Forget This Biotech Stock’s Rally Signals Fresh Jump
NovaGen Therapeutics rockets after a major AI-driven deal, highlighting a rare biotech upside amid a cooling AI market.
Introduces a practical approach combining zero-based budgeting with cash envelopes, detailing setup and everyday usage.
28,655 articlesNovaGen Therapeutics rockets after a major AI-driven deal, highlighting a rare biotech upside amid a cooling AI market.
UniCredit announces a $40 billion bid for Germany’s second-largest bank with a 4% premium, but early signals point to...
With a 15-day deadline to resolve Iran tensions, U.S. markets brace for a volatile April as traders weigh oil, stocks...
IonQ delivers a standout Q1 and a fresh price-target outlook that signals potential triple-digit gains over the next ...
A $2 million retirement portfolio can support roughly $42,000 in real annual spending for a 65-year-old over 30 years...
A broad crypto rout drags BitMine Immersion Technologies and Strategy lower as Ethereum tumbles about 7% in 24 hours....
Friday’s slide left many investors asking what’s next. This guide highlights three stocks that bounce back, why they ...
AI demand has sparked a rapid rally in memory stocks, but signs of inventory normalization and pricing pressure pose ...
A wave of AI-generated wedding memes and rumors grabbed headlines, but the real lesson isn’t about celebrity gossip—i...
Global markets surged as word of a U.S.-Iran accord renewed optimism about Gulf stability and energy supply. Stocks c...
A cheaper Brazil-focused ETF is outperforming its larger peer in 2026, prompting a rethink of how investors access Br...
Fidelity’s Active Large Growth ETF threads a narrow but meaningful edge over passive peers as AI-enabled demand fuels...